Figure S16 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Year: 2026
Type: other
Abstract: Figure S16. Stability assessment of [225Ac]Macropa-PEG4-YS5-MMAE over 7-day storage in PBS. (A) Drug-to-antibody ratio (DAR) was measured on Day 0, Day 4, and Day 7 using UV spectrophotometry. DAR remained stable between 2.2 and 2.8, confirming MMAE retention over time. (B) Magnetic bead–based binding assay performed on Day 7 demonstrated preserved immunoreactivity of [225Ac]Macropa-PEG4-YS5-MMAE to CD46 antigen. Binding was significantly reduced in the presence of excess unlabeled YS5 (blocking group) or in the absence of CD46. (C) CellTiter-Glo viability assay using 22Rv1 cells treated with [225Ac]Macropa-PEG4-YS5-MMAE on Day 0 or after 7 days of storage in PBS showed no significant difference in cytotoxic activity, confirming functional stability.
Authors: Anil P. Bidkar, Scott Bidlingmaier, Anju Wadhwa, Ellis Mayne, Athira Raveendran, Shubhankar Naik, Cheng Xue, Megha Basak, Kondapa Naidu Bobba, Bonell Patiño-Escobar, Nancy Greenland, Juan Antonio Camara Serrano, Veronica Steri, Jonathan Chou, Arun Wiita, Jiang He, David M. Wilson, Rahul Aggarwal, Henry F. VanBrocklin, Youngho Seo, Bin Liu, Robert R. Flavell
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7165025323